Background. Marked increases in Clostridium difficile infection (CDI) incidence, driven by epidemic strain spread, is a global phenomenon.
In recent years there has been a significant change in the epidemiology of C. difficile infection (CDI) [1] . From 2002 to 2003 the emergence of a previously uncommon but more virulent strain, known as the C. difficile North American pulsed field type 1 (NAP1), or ribotype 027, radically altered the epidemiological pattern of CDI in North America and then in Northern Europe [2, 3] . Alarming increases in CDI rates were reported initially in Canada and the United States, and CDI cases associated with severe disease, higher mortality, increased risk of recurrence, and more complications were linked to this emergent strain. A similar pattern of outbreaks associated with severe disease occurred in Europe [2] [3] [4] . More than 55 000 CDI cases were reported in England in [2007] [2008] , of which 20% were in younger age groups previously not considered to be high risk. The number of death certificates mentioning C. difficile increased each year in England and Wales, from 2238 in 2004 to 8324 in 2007 [5] .
From 2007, all acute National Health Service (NHS) hospitals in England were required to report all cases of CDI in patients aged ≥2 years, and mandatory reduction targets for CDIs were established [6, 7] . Responding to a national public health need, the Health Protection Agency (HPA) created the Clostridium difficile Ribotyping Network (CDRN) for England, as part of an enhanced surveillance program for C. difficile in 2007 [8] . CDRN consists of several regional microbiology laboratories in England, which aim to provide timely access to C. difficile culture and ribotyping according to standardized criteria for submission of fecal samples. We report on data analyzed from the first 3 (financial) years of delivery of this national molecular epidemiology service for C. difficile (2007) (2008) (2009) (2010) , and relate these to changes in the epidemiology of CDI in England.
METHODS, DATA COLLECTION, AND ANALYSIS
The CDRN Service for England is delivered via 7 regional diagnostic microbiology laboratories: Leeds (Reference Laboratory, Leeds General Infirmary), Birmingham (Public Health Laboratory, Birmingham), Cambridge (Addenbrooke's Hospital), London (University College Hospital), Manchester (Manchester Royal Infirmary), Newcastle (Newcastle Royal Victoria Infirmary) and Southampton (Health Protection Agency, Southampton General Hospital). Fecal samples to be submitted to the CDRN per incident are agreed prospectively with a microbiologist in respective CDRN laboratories. Criteria used to access the service include investigation of increases in the frequency of CDI cases (or high baseline rates), and increased severity, recurrence, complications, or mortality associated with CDI. A standardized request form for clinical and epidemiological data is used and is available via a web-based electronic requesting (and reporting) portal. The request form collects demographic information including patient name, sex, and date of birth; the name of the requesting hospital and the reason for ribotyping request; and antibiotic history in the 30 days before the onset of CDI symptoms. Optional outcome data may be submitted via a set of closed questions requiring yes/no responses to questions regarding admission to the intensive care unit as a result of CDI, death within 30 days of onset of CDI, occurrence of toxic megacolon or pseudomembranous colitis, or requirement for a surgical procedure as a result of CDI.
Culture and ribotyping were performed according to standardized methods [9, 10] . The target turnaround time for delivery of ribotyping results, including the time for C. difficile culture, is <2 weeks. CDRN laboratories participate 1-2 times per year in a quality assessment scheme, comprising the identification of a set of operator-blinded strains, organized by the Leeds reference laboratory.
Statistical Analysis
All analyses were carried out using Stata software, version 8.0 (StataCorp). Prevalence was calculated as percentages. Proportions were calculated for categorical variables using the χ 2 test.
Analysis of clinical and demographic risk factors associated with mortality was performed by logistic regression analysis. (7) 1135 (10) 001 162 (9) 299 (7) 371 (7) 832 (7) 014/020 a 54 (3) 220 (5) 433 (8) 707 (6) 015* 46 (2) 224 (5) 330 (6) 600 (5) 002* 57 (3) 238 (6) 302 (6) 597 (5) 078* 35 (2) 149 (4) 285 (5) 469 (4) 005* 27 (2) 118 (3) 213 (4) 358 (3) 023* 21 (1) 112 (3) 149 (3) 282 (3) 016* 0 79 (2) 139 (3) 218 (2) Others* 201 (11) 731 (17) 1514 (29) 2446 ( (7) 25 (42) 30 (51) South East & West regions had significant year-on-year increases in the prevalence of ribotypes 002, 015, and 078 (all P < .05), but no significant change overall in ribotype 027. There was a significant increase in other ribotypes not included in the 10 most prevalent (Table 1) . When these were stratified by year and region, there was a proportional yearly increase of other ribotypes in all regions (data not shown). Analysis of documented complications as a result of CDI and antibiotic usage is described in Tables 3 and 4 More than 85% of the patients for whom samples were submitted to CDRN were aged >65 years. Analysis of the available data on demographic and clinical risk factors showed that age >65 years, ribotype 027, severe disease (including development of reported pseudomembranous colitis, toxic megacolon, and abdominal surgery as a result of CDI) and exposure to ≥2 antibiotics were significantly associated with 30-day all-cause mortality (Table 5 ). There was a significant decrease in allcause mortality between 2007-2008 and the subsequent years. Because of the number of missing values (only 40%-50% of the responses recorded data on mortality) a robust multivariate model could not be constructed and is not reported.
RESULTS

In
DISCUSSION
The CDRN service was initiated by the HPA in 2007 in response to public health need. The human and economic cost of CDI is considerable [12, 13] . Healthcare institutions across England reported increasing frequency, morbidity, and mortality to the HPA as part of mandatory reporting of C. difficile laboratory reports, which had been in place since 2004 [11, 12] . Our analysis of 3 years of CDRN data is therefore likely biased toward the indications listed for requesting ribotyping. Although about half of the cases were associated with clustering, unexplained increases in CDI rate and case severity were also prominent reasons for referral. Furthermore, as the ribotyping coverage by CDRN increased markedly, more than tripling the numbers of samples processed in the first 3 years of operation, and reaching more than 1 in 5 of all recorded CDI cases in England by 2009-2010, it is very likely that these data accurately represent the regional and national prevalence of C. difficile ribotypes.
The launch of CDRN coincided with the setting of mandatory reductions for CDIs in NHS hospitals in England [6] [7] [8] [14] . In retrospect, it is possible that C. difficile 027 was introduced in the United Kingdom in 2002-2003, as the rate of C. difficile reporting increased around this time. Since its inception, CDRN data have demonstrated that the ribotype 027 strain of C difficile is the most prevalent in England. We believe that by providing timely data on ribotypes to infection prevention teams across England, CDRN has enabled the targeting of interventions and resources on high-incidence CDI settings and particularly those with a high prevalence of ribotype 027. As the proportion of CDIs caused by ribotype 027 has declined markedly, significant increases have been seen in the prevalence of other C. difficile clones, especially ribotypes 014/020, 015, 002, 078, 005, 023, and 016. This phenomenon may reflect the success of control measures to reduce cross-infection in hospitals caused by the predominant epidemic strain, or it may reflect the emergence of strains such as ribotype 078, as reported elsewhere [15] . Also, increased sample submission to CDRN may be expected to lead to an amplification of the relative contribution of other C. difficile ribotypes, including emergent strains, among recorded cases. The largest variations in prevalence were seen with ribotypes 027, 002, 015, and 078, and there were clear regional differences. Significant yearly trends were seen for all 4 ribotypes in the London, North East, North West, and Yorkshire & Humber regions, with a decreasing rate of ribotype 027, and increases in ribotypes 002, 015, and 078. The East & West Midlands, East Anglia and the South East & West regions had significant year-on-year increases in the prevalence of ribotypes 002, 015, and 078, but no significant change overall in the rate of ribotype 027. Such analyses provide useful indicators of possible regional differences and time trends to indicate potential emergent or declining C. difficile ribotypes. A 2008 pan-European C. difficile period prevalence study, carried out in 69 hospitals in 28 countries, found that the 8 most common ribotypes were 001, 002, 012, 014, 015, 018, 027, and 078 [16] . Of these 8 types, 6 featured in the most prevalent ribotypes in England (the exceptions being ribotypes 012 and 018). The most prominent ribotype that is seen in England but rarely elsewhere is 106. The epidemic nature of ribotype 106 in the United Kingdom with very limited spread elsewhere remains unexplained.
Clinical data retrieval on the cases in this cohort showed that there was a significant decrease in reports of all complications, including mortality from 2007-2008 to [2009] [2010] . This likely reflects a reduction in the prevalence ribotype 027, but also an improved understanding of the need for increased clinical vigilance and aggressive intervention with CDIs caused by virulent strains and enhanced infection control [4, 17] . Response rates providing information on complications/ outcomes varied year on year, with, for example, about 50% of requests providing follow-up information on all-cause mortality. However, data were available from a large total number of CDI cases and provide useful epidemiological information as a potential early warning system for emergent virulent strains, and to record an improvement in outcomes with time. Analysis of risks associated with all-cause mortality showed that ribotype 027 was significantly associated with mortality. Other significant risk factors evident from the univariate analysis were age >65 years, severe disease as indicated by the clinician (includes toxic megacolon and pseudomembranous colitis), surgical intervention as a result of CDI, and exposure to ≥2 antibiotics. The approximately doubled risk of death associated with ribotype 027 is consistent with data from other settings, particularly in Canada where the combined effect of age and ribotype 027 was reported [18] . Severe disease was predictably a significant risk factor for mortality in all 3 years. Surgery was a risk factor for mortality in 2007-2008 and 2008-2009 , but not in 2009-2010 (data not shown). It is tempting to hypothesize that the ribotype 027 epidemic led to important lessons on the benefit of early surgical intervention [19, 20] . However, as discussed below, data limitations mean that definitive conclusions relating to outcome are not possible.
We had better response rates for data on antibiotic usage (almost 80%), which changed significantly over the first 3 years of CDRN's existence. In 2007-2008, cephalosporins were the most commonly reported agents, followed by fluoroquinolones. There was a significant reduction in the usage of both classes by 2009--2010, probably secondary to NHS advice to minimize the use of such antibiotics [1, 21] . There were significant increases in reports of co-amoxiclav and piperacillin-tazobactam over the 3 years. These data likely reflect real changes in prescribing of systemic antibiotics, as one aspect of preventive measures for CDI [22, 23] , as opposed to real changes in which antibiotics were causing CDI. Individual antibiotics associated with mortality on univariate analysis were cephalosporins, fluoroquinolones, and amoxicillin. However, in those patients for whom recent antibiotic exposure was reported, the proportion who received >1 antimicrobial agent was stable over the 3 years (61%-66%); the proportion who received at least 3 antibiotics decreased from 30% to 25% to 17%. Such data emphasize the problems inherent in determining cause and effect for individual antibiotics in CDI cases [24] .
Critically, user access to the CDRN is based on clinical need. As with any surveillance scheme, initial uptake is invariably less enthusiastic. Nevertheless, the smallest annual sample size was >2100 patients. In the same year (2007-2008) a smaller surveillance study, which was designed to provide a representative sample of the C. difficile strains causing infections in hospitals in England, collected 677 isolates from 186 hospitals [25] . In this systematically collected cohort, ribotyping showed that PCR ribotype 027 was by far the most common strain isolated from symptomatic patients, accounting for >41.3% of isolates in English hospitals. Ribotypes 106 and 001 were the second and third most common strains (20.2% and 7.8%, respectively). Thus, these data are very similar to the results we recorded for nonsystematically collected samples, and imply that our results truly reflect the prevalent strains at this time.
Our study is also subject to the following limitations. The criteria used to access the CDRN may not have been followed strictly by all requesters. The cohort was a mixture of both clustered and sporadic (eg, severe) cases. From Tables 3 and 5 it is evident that there were varying numbers of denominator responses. This was unavoidable especially when launching a nationwide service. Analysis of outcome data including reports of complications associated with CDI and the analysis on risks for all-cause mortality is biased as only 40%-50% of responders reported these data. Reporting bias may likely lead to the overrecording of complications including death, and we therefore acknowledge that there is a danger of overinterpreting both trends and the effect of individual variables with regard to outcomes. Even so, the analyses provide crude indicators of outcomes and risks that predict mortality in CDI. In so doing, it is important to note the difficultly in determining the relationship between death and CDI. As discussed previously, however, the mortality trends we report here do mirror those seen in national data where deaths are categorized into those where C. difficile is mentioned and where this was considered to be the underlying cause. The significant decrease in the mortality associated with C. difficile ribotype 027 could be ascribed to a number of factors, including decreasing prevalence of this strain, evolving clones with reduced virulence, improved case management, and enhanced infection control.
Further appropriately sampled and powered prospective studies that focus on clinical and controlled demographic risk factors for outcomes would enhance our understanding of the changing epidemiology of morbidity and mortality associated with CDI. The CDRN service continues to develop, with coverage in Northern Ireland from 2010. Also, enhanced molecular epidemiology is now being offered using multilocus variable-number tandem-repeat analysis to confirm or refute suspected CDI case clusters as detected through ribotyping [26] .
Notes
